These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 22768603)

  • 1. [Perspective of new and future treatment of type 2 diabetes].
    Sasaoka T
    Nihon Rinsho; 2012 May; 70 Suppl 3():707-15. PubMed ID: 22768603
    [No Abstract]   [Full Text] [Related]  

  • 2. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
    Vilsbøll T; Holst JJ; Knop FK
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dysregulation of glucagon secretion in diabetes and intra-islet insulin effect on alpha-cells].
    Kawamori D
    Nihon Rinsho; 2012 May; 70 Suppl 3():212-7. PubMed ID: 22768522
    [No Abstract]   [Full Text] [Related]  

  • 4. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
    Ortúzar N
    ChemMedChem; 2013 Apr; 8(4):535-7. PubMed ID: 23529925
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
    Meneilly GS; Elahi D
    J Am Geriatr Soc; 2006 Mar; 54(3):554-5. PubMed ID: 16551338
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention.
    Karaca M; Magnan C; Kargar C
    Diabetes Metab; 2009 Apr; 35(2):77-84. PubMed ID: 19251449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glucokinase activators].
    Shirakawa J; Terauchi Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():721-7. PubMed ID: 22768605
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses.
    Rijkelijkhuizen JM; McQuarrie K; Girman CJ; Stein PP; Mari A; Holst JJ; Nijpels G; Dekker JM
    Metabolism; 2010 Apr; 59(4):502-11. PubMed ID: 19846181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
    Pols TW; Auwerx J; Schoonjans K
    Gastroenterol Clin Biol; 2010; 34(4-5):270-3. PubMed ID: 20444564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet cell function: alpha and beta cells--partners towards normoglycaemia.
    Göke B
    Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.
    Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S
    Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Care of type 2 diabetes: where do the new medications fit?
    Clem CO; Heins JR
    S D Med; 2015 Mar; 68(3):126-7. PubMed ID: 25906502
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
    Takasu T; Takakura S; Kaku S
    Nihon Yakurigaku Zasshi; 2015 Jan; 145(1):36-42. PubMed ID: 25743234
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of alpha cell in islets on beta cell function].
    Cheng LY; Xu SQ; Zhang WJ
    Sheng Li Ke Xue Jin Zhan; 2011 Oct; 42(5):394-7. PubMed ID: 22242412
    [No Abstract]   [Full Text] [Related]  

  • 17. The mechanisms of action for treatments of type 2 diabetes.
    Leahy JJ
    Diabetes Educ; 2007; 33 Suppl 5():101S-4S. PubMed ID: 17548896
    [No Abstract]   [Full Text] [Related]  

  • 18. [C-peptide: a by-product of insulin biosynthesis or an active peptide hormone?].
    Mavrakanas T; Bastide D
    Presse Med; 2009 Jan; 38(1):68-72. PubMed ID: 18951760
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketosis-prone atypical diabetes: glucagon is there, too.
    Lefèbvre P
    Diabetes Care; 2013 Jan; 36(1):8-10. PubMed ID: 23264286
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Glucocorticoid Treatment on β- and α-Cell Mass in Japanese Adults With and Without Diabetes.
    Sato S; Saisho Y; Inaishi J; Kou K; Murakami R; Yamada T; Itoh H
    Diabetes; 2015 Aug; 64(8):2915-27. PubMed ID: 25883114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.